HLA-C and neoplasm: A summary of these immunogenic MHC-I-restricted epitopes, as well as four non-mutated previously characterised tumour antigens40–42, and their predicted binding affinities of wild type (WT) versus mutant (MT) peptide to MHC is shown; these predictions revealed that pMHCs in our system span the spectrum of mutant peptide-MHC affinity and specificity for mutant peptide (ratio of mutant to wild type affinity for MHC) (Fig. 1e, f).